GO:0005132 type I interferon receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005132 (type I interferon receptor binding) is a molecular function describing the binding of a ligand to the heterodimeric IFNAR1/IFNAR2 receptor complex.
• The type I interferon receptor is composed of two subunits, IFNAR1 and IFNAR2, which together bind all type I interferons including IFN-alpha and IFN-beta.
• Binding of type I interferons to their receptor activates the JAK-STAT signaling pathway, leading to transcription of interferon-stimulated genes.
• Type I interferon receptor binding is critical for antiviral defense, immune regulation, and has context-dependent roles in cancer and inflammatory diseases.
• Dysregulation of this binding event is implicated in autoimmunity, viral immune evasion, and resistance to immune checkpoint blockade.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of receptor binding and downstream signaling.
Description
Type I interferon receptor binding (GO:0005132) is a molecular function that describes the specific interaction between a ligand and the type I interferon receptor, a heterodimeric complex composed of the alpha subunit (IFNAR1) and the beta subunit (IFNAR2). This binding event is the first step in a signaling cascade that is central to innate antiviral immunity and immune modulation. The receptor binds all type I interferons, including multiple IFN-alpha subtypes and IFN-beta, and the affinity and kinetics of these interactions determine the strength and duration of downstream signaling. Understanding the molecular details of this binding is essential for researchers studying viral pathogenesis, autoimmune diseases, and cancer immunology. The type I interferon receptor is expressed on nearly all nucleated cells, and its engagement triggers phosphorylation of JAK kinases and STAT transcription factors, leading to the expression of hundreds of interferon-stimulated genes. The functional outcome of receptor binding is highly context-dependent, ranging from potent antiviral responses to anti-inflammatory effects in the lung and modulation of immune cell subsets. Recent studies have shown that type I interferon signaling can induce cell-intrinsic PD-1 in melanoma, which has implications for immune checkpoint blockade therapy. Furthermore, autoantibodies against type I interferons can neutralize receptor binding and are associated with severe viral infections. Given its central role in immunity, the type I interferon receptor binding function is a major focus of biomedical research. Viruses have evolved strategies to inhibit this interaction, such as the African swine fever virus p22 protein, which promotes degradation of the type I interferon receptor. These examples underscore the importance of precise experimental models to study receptor binding and its downstream consequences. CRISPR-based gene editing offers powerful tools to create knockout, point-mutation, knock-in, and overexpression cell models to investigate the molecular determinants of type I interferon receptor binding and signaling.
type I interferon receptor binding At A Glance
| GO ID | GO:0005132 |
|---|---|
| GO term | type I interferon receptor binding |
| Ontology | molecular_function |
| Synonym | IFNAR1 binding, IFNAR2 binding, IFNAR binding, interferon-alpha/beta receptor binding |
| Major function | Binding of type I interferons to the IFNAR1/IFNAR2 heterodimeric receptor, initiating JAK-STAT signaling |
| Definition | Binding to an interferon-type I receptor, a heterodimeric complex composed of an alpha subunit (IFNAR1) and a beta subunit (IFNAR2) |
| Related ligands | IFN-alpha subtypes, IFN-beta, IFN-omega, IFN-epsilon, IFN-kappa |
| Receptor subunits | IFNAR1 (alpha subunit), IFNAR2 (beta subunit) |
| Downstream pathway | JAK-STAT signaling pathway |
What Is GO:0005132?
According to the Gene Ontology, GO:0005132 (type I interferon receptor binding) is defined as the binding to an interferon-type I receptor, a heterodimeric complex composed of an alpha subunit (IFNAR1) and a beta subunit (IFNAR2). This molecular function encompasses the interaction between any type I interferon ligand (such as IFN-alpha or IFN-beta) and the extracellular domains of the IFNAR1/IFNAR2 complex. The term includes the binding of the ligand to either subunit or to the assembled heterodimer, and it is a prerequisite for receptor activation and subsequent intracellular signaling.
Why Is type I interferon receptor binding Important in Cell Biology?
Type I interferon receptor binding is a critical molecular event that initiates the innate immune response to viral infections and shapes adaptive immunity. It is essential for host defense against a wide range of viruses, and its dysregulation contributes to autoimmune diseases, chronic viral infections, and cancer. The binding event is also a target for viral immune evasion strategies and for therapeutic interventions, including recombinant interferons used in clinical practice. Understanding the precise molecular interactions and the factors that regulate receptor binding is therefore of high biomedical relevance.
• Initiates antiviral defense by activating JAK-STAT signaling and interferon-stimulated genes.
• Modulates immune cell function, including B cell memory subsets during chronic viral infection.
• Plays a context-dependent role in cancer, including induction of PD-1 in melanoma cells.
• Is targeted by viral proteins to evade immune responses, such as ASFV p22.
• Autoantibodies against type I interferons can neutralize receptor binding and increase susceptibility to severe viral infections.
• Has anti-inflammatory roles in the lung, influencing respiratory viral pathogenesis.
• Regulates macrophage-mediated protection against SARS-CoV-2.
• Serves as a therapeutic target for recombinant interferons and decoy receptors.
• Provides a model system for studying receptor-ligand specificity and signaling bias.
• Enables CRISPR-based functional genomics to identify modulators of interferon signaling.
Molecular Mechanism of type I interferon receptor binding
Ligand recognition and receptor assembly
In simple terms: Type I interferons bind to two receptor subunits on the cell surface, bringing them together to start a signal.
The type I interferon receptor is a heterodimeric complex composed of IFNAR1 and IFNAR2. Type I interferons, such as IFN-alpha and IFN-beta, bind to the extracellular domains of these subunits with varying affinities. IFNAR2 typically provides the high-affinity binding site, while IFNAR1 contributes to complex stability and signaling specificity. The binding of the ligand induces a conformational change that brings the two receptor subunits into close proximity, allowing their associated JAK kinases (JAK1 and TYK2) to phosphorylate each other and the receptor cytoplasmic tails.
JAK-STAT activation and signal transduction
In simple terms: Once the receptor is bound, enzymes inside the cell add phosphate tags to proteins, which then travel to the nucleus to turn on antiviral genes.
Following receptor dimerization, JAK1 (associated with IFNAR2) and TYK2 (associated with IFNAR1) are activated by trans-phosphorylation. These kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, creating docking sites for STAT proteins, primarily STAT1 and STAT2. STAT1 and STAT2 are then phosphorylated, form heterodimers, and associate with IRF9 to form the ISGF3 complex. This complex translocates to the nucleus and binds to interferon-stimulated response elements (ISREs) to initiate transcription of interferon-stimulated genes.
Negative regulation and receptor turnover
In simple terms: The cell has brakes to stop the interferon signal, including proteins that degrade the receptor or inhibit its activity.
To prevent excessive or prolonged signaling, type I interferon receptor binding and downstream signaling are tightly regulated. Negative regulators include SOCS proteins, which inhibit JAK kinase activity, and phosphatases such as SHP-1 and SHP-2. Additionally, receptor ubiquitination and degradation can downregulate the receptor complex. For example, the African swine fever virus p22 protein promotes TAX1BP1-mediated degradation of the type I interferon receptor, thereby inhibiting JAK-STAT signaling. This highlights how viral pathogens can target receptor stability to evade immune responses.
Ligand-specific signaling and biased agonism
In simple terms: Different interferons can produce different responses even though they bind the same receptor, because they interact in slightly different ways.
Although all type I interferons bind the same IFNAR1/IFNAR2 complex, they can elicit distinct signaling outcomes, a phenomenon known as biased agonism. For example, IFN-beta has a higher affinity for IFNAR1 than IFN-alpha subtypes, which can lead to differential activation of STAT proteins and gene expression profiles. The molecular basis for these differences lies in the binding epitopes and the stability of the ternary complex. Understanding these nuances is important for the development of interferon-based therapeutics with improved efficacy and reduced side effects.
Receptor binding in immune cell subsets
In simple terms: Different immune cells respond to interferon in unique ways, which affects how the body fights infections and remembers them.
Type I interferon receptor binding triggers cell-type-specific responses. In chronic viral infection, type I interferons induce an epigenetically distinct memory B cell subset that contributes to long-term immunity. In the lung, type I interferon signaling can have anti-inflammatory roles, modulating the severity of respiratory viral infections. Nerve- and airway-associated interstitial macrophages utilize type I interferon signaling to mitigate SARS-CoV-2 pathogenesis. These examples illustrate that the consequences of receptor binding are highly dependent on the cellular context and the presence of other signals.
Key Genes Involved in GO:0005132 type I interferon receptor binding
The following genes and proteins are central to type I interferon receptor binding and its downstream signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNAR1 | Alpha subunit of the type I interferon receptor; binds type I interferons and mediates signaling | Knockout studies reveal its essential role in antiviral defense; target for viral evasion |
| IFNAR2 | Beta subunit of the type I interferon receptor; high-affinity ligand binding | Knockout and point mutations dissect ligand specificity and signaling |
| IFNA1 | Encodes IFN-alpha 1, a type I interferon ligand | Used in overexpression and binding assays to study receptor activation |
| IFNB1 | Encodes IFN-beta, a type I interferon ligand with high affinity for IFNAR1 | Key ligand for studying biased agonism and antiviral responses |
| JAK1 | Janus kinase associated with IFNAR2; phosphorylates STAT proteins | Knockout models show loss of interferon signaling |
| TYK2 | Janus kinase associated with IFNAR1; essential for signal transduction | Point mutations affect kinase activity and interferon responses |
| STAT1 | Transcription factor activated by JAKs; forms ISGF3 complex | Knockout models demonstrate its role in interferon-stimulated gene expression |
| STAT2 | Transcription factor activated by JAKs; forms ISGF3 complex | Essential for type I interferon-specific signaling |
| IRF9 | DNA-binding subunit of ISGF3; recognizes ISREs | Knockout reduces interferon-stimulated gene induction |
| SOCS1 | Negative regulator of JAK-STAT signaling | Overexpression suppresses interferon responses |
| SOCS3 | Negative regulator of JAK-STAT signaling | Modulates interferon signaling in various cell types |
| PTPN6 | Encodes SHP-1 phosphatase; negative regulator of JAK-STAT | Knockout enhances interferon signaling |
| PTPN11 | Encodes SHP-2 phosphatase; regulates JAK-STAT | Point mutations affect interferon responsiveness |
| TAX1BP1 | Autophagy receptor involved in degradation of IFNAR1 | Targeted by viral proteins to downregulate receptor |
| PDCD1 | Encodes PD-1; induced by type I interferon signaling in melanoma | Knockout or knockdown affects immune checkpoint blockade response |
| IFITM3 | Interferon-stimulated gene; restricts viral entry | Overexpression studies show antiviral activity |
| MX1 | Interferon-stimulated gene; GTPase with antiviral activity | Knockout increases viral susceptibility |
| OAS1 | Interferon-stimulated gene; activates RNase L | Polymorphisms affect antiviral responses |
How Is type I interferon receptor binding Regulated?
Type I interferon receptor binding and signaling are regulated at multiple levels. Receptor expression levels are controlled by transcriptional and post-transcriptional mechanisms, including microRNAs and ubiquitination. Ligand availability is regulated by interferon production and secretion, which is induced upon pathogen recognition. Negative feedback loops involving SOCS proteins and phosphatases (SHP-1, SHP-2) attenuate signaling. Additionally, viral proteins can directly target the receptor for degradation, as seen with ASFV p22. Autoantibodies against type I interferons can neutralize receptor binding, providing another layer of regulation in autoimmune and infectious contexts.
type I interferon receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNAR1 | Viral infections, autoimmunity | Knockout mice or cell lines to study susceptibility |
| IFNAR2 | Viral infections, interferonopathies | Point mutation knock-in to dissect ligand binding |
| PDCD1 | Melanoma, immune checkpoint blockade response | Overexpression or knockout in melanoma cell lines |
| TAX1BP1 | Viral immune evasion (ASFV) | Knockout to study receptor degradation |
| IFNB1 | Multiple sclerosis, viral infections | Overexpression for therapeutic studies |
Type I interferon receptor binding in cancer and immunotherapy
Type I interferon signaling has complex roles in cancer. In melanoma, type I interferon signaling induces cell-intrinsic PD-1 expression, and its inhibition can antagonize immune checkpoint blockade. This suggests that receptor binding and downstream signaling can modulate tumor responses to immunotherapy. Understanding how type I interferon receptor binding affects PD-1 induction may lead to improved therapeutic strategies.
Viral immune evasion and receptor degradation
Viruses have evolved mechanisms to inhibit type I interferon receptor binding or downstream signaling. The African swine fever virus p22 protein promotes TAX1BP1-mediated degradation of the type I interferon receptor, thereby inhibiting JAK-STAT signaling and evading host immunity. This highlights the importance of receptor stability in antiviral defense and suggests potential targets for antiviral therapy.
Autoantibodies and neutralizing mechanisms
Autoantibodies against type I interferons can neutralize receptor binding and are associated with severe viral infections, including life-threatening COVID-19. A recent study revealed the neutralizing mechanisms of these autoantibodies and designed inhibitory decoys that could be used therapeutically. This underscores the clinical relevance of type I interferon receptor binding in infectious diseases.
Type I interferon signaling in lung inflammation and COVID-19
Type I interferon signaling has anti-inflammatory roles in the lung, and its dysregulation can affect the severity of respiratory viral infections. Nerve- and airway-associated interstitial macrophages utilize type I interferon signaling to mitigate SARS-CoV-2 pathogenesis. These findings suggest that modulating type I interferon receptor binding could be a therapeutic strategy for COVID-19 and other respiratory diseases.
From type I interferon receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IFNAR1 knockout abolish type I interferon signaling? | IFNAR1 knockout cell line (e.g., HEK293, A549) |
| Which residues in IFNAR2 mediate high-affinity ligand binding? | Point mutation knock-in of IFNAR2 |
| Can a tagged IFNAR1 be used to track receptor trafficking? | Knock-in of fluorescent or epitope tag on IFNAR1 |
| Does overexpression of IFN-beta enhance antiviral responses? | Overexpression cell line with IFN-beta construct |
| What is the role of TYK2 in receptor binding-induced signaling? | TYK2 knockout or point mutation |
| Can CRISPR screening identify novel regulators of interferon receptor binding? | Genome-wide CRISPR knockout library followed by interferon challenge |
How to Study the type I interferon receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Genes required for interferon receptor binding/signaling | Identify novel modulators |
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterize ligand-receptor interactions |
| Phospho-STAT flow cytometry | STAT1/STAT2 phosphorylation | Assess receptor activation at single-cell level |
| RNA-seq | Global gene expression changes | Measure ISG induction |
| Immunoblotting | Protein phosphorylation and degradation | Validate signaling and receptor turnover |
| Co-immunoprecipitation | Protein-protein interactions | Study receptor complex assembly |
| Luciferase reporter assay | ISRE-driven transcription | Quantify interferon signaling |
| ELISA | Cytokine secretion | Measure interferon production |
CRISPR knockout screens for interferon signaling modulators
Genome-wide CRISPR knockout screens can identify genes that regulate type I interferon receptor binding and downstream signaling. Cells are transduced with a lentiviral sgRNA library, selected, and challenged with type I interferon or virus. Enrichment or depletion of sgRNAs reveals essential genes. This approach has been used to uncover modulators of interferon responses in cancer and immune cells.
Biochemical binding assays (SPR, BLI)
Surface plasmon resonance (SPR) and biolayer interferometry (BLI) measure real-time binding kinetics between type I interferons and the IFNAR1/IFNAR2 complex. These methods provide quantitative data on affinity (KD), association and dissociation rates, and can be used to compare different interferon subtypes or mutant receptors.
Phospho-STAT flow cytometry and immunoblotting
Phosphorylation of STAT1 and STAT2 is a direct readout of type I interferon receptor activation. Flow cytometry with phospho-specific antibodies allows single-cell analysis, while immunoblotting provides bulk quantification. These methods are used to assess the functional consequences of receptor binding and to validate knockout or point-mutation models.
Transcriptomic profiling of interferon-stimulated genes
RNA-seq or targeted gene expression panels can measure the induction of interferon-stimulated genes (ISGs) following receptor binding. This provides a global view of signaling outcomes and can reveal cell-type-specific responses. It is often combined with CRISPR models to link genotype to transcriptional phenotype.
How CRISPR Can Be Used to Study GO:0005132 type I interferon receptor binding
Knockout
CRISPR knockout of IFNAR1 or IFNAR2 completely abolishes type I interferon receptor binding and downstream signaling. These models are used to study the role of interferon signaling in antiviral defense, immune cell function, and cancer. For example, IFNAR1 knockout cells are resistant to the effects of type I interferons and are valuable for dissecting specific signaling pathways.
Point Mutation
Point mutations in IFNAR1 or IFNAR2 can be introduced to dissect the molecular determinants of ligand binding and receptor activation. For instance, mutating specific tyrosine residues in the intracellular domain can prevent STAT recruitment without affecting ligand binding. These models help distinguish between binding affinity and signaling efficacy.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the endogenous IFNAR1 or IFNAR2 loci allows for tracking receptor expression, localization, and trafficking in live cells. This is useful for studying receptor internalization and degradation following ligand binding.
Overexpression
Overexpression of type I interferons (e.g., IFN-beta) or receptor subunits can enhance signaling and is used to study gain-of-function effects. Overexpression models are also valuable for producing large amounts of recombinant proteins for structural and biochemical studies.
How EDITGENE Supports type I interferon receptor binding Research
Researchers studying type I interferon receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for type I interferon receptor binding research.
Frequently Asked Questions About type I interferon receptor binding
What is type I interferon receptor binding?
Type I interferon receptor binding (GO:0005132) is the molecular function of a ligand binding to the heterodimeric IFNAR1/IFNAR2 receptor complex, initiating JAK-STAT signaling.
What genes are involved in type I interferon receptor binding?
Key genes include IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT2, and IRF9, as well as ligands such as IFNA1 and IFNB1.
What is the GO ID for type I interferon receptor binding?
The Gene Ontology ID is GO:0005132.
How does type I interferon receptor binding activate signaling?
Ligand binding induces receptor dimerization, activating JAK kinases that phosphorylate STAT proteins, which then translocate to the nucleus to induce interferon-stimulated genes.
Which diseases are associated with type I interferon receptor binding?
Dysregulation is linked to viral infections, autoimmune diseases, cancer, and severe COVID-19.
What are the subunits of the type I interferon receptor?
The receptor is a heterodimer of IFNAR1 (alpha subunit) and IFNAR2 (beta subunit).
How can CRISPR be used to study type I interferon receptor binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of receptor function and signaling.
What is the role of IFNAR1 in type I interferon signaling?
IFNAR1 is essential for signal transduction; its degradation by viral proteins inhibits JAK-STAT signaling.
What is the difference between type I and type II interferon receptors?
Type I interferon receptor binds IFN-alpha/beta and consists of IFNAR1/IFNAR2, while type II receptor binds IFN-gamma and consists of IFNGR1/IFNGR2.
How do autoantibodies affect type I interferon receptor binding?
Autoantibodies can neutralize type I interferons, preventing receptor binding and increasing susceptibility to severe viral infections.
Conclusion
Type I interferon receptor binding (GO:0005132) is a fundamental molecular function that initiates antiviral and immune-modulatory signaling. Its precise regulation is critical for health, and its dysregulation contributes to a range of diseases. Continued research using advanced CRISPR models will further elucidate the mechanisms and therapeutic potential of targeting this interaction.
References
- 1. Holzgruber J et al.. 2024. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade.. Nat Commun 15(1):7165 PMID: 39187481
- 2. Cooper L et al.. 2024. Type I interferons induce an epigenetically distinct memory B cell subset in chronic viral infection.. Immunity 57(5):1037-1055.e6 PMID: 38593796
- 3. Groen K et al.. 2025. Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design.. J Exp Med 222(6) PMID: 40111224
- 4. Ren H et al.. 2025. The African swine fever virus p22 inhibits the JAK-STAT signaling pathway by promoting the TAX1BP1-mediated degradation of the type I interferon receptor.. PLoS Pathog 21(7):e1013319 PMID: 40668839
- 5. Domanski P et al.. 1996. The type-I interferon receptor. The long and short of it.. Cytokine Growth Factor Rev 7(2):143-51 PMID: 8899292
- 6. Feng J et al.. 2024. Anti-inflammatory roles of type I interferon signaling in the lung.. Am J Physiol Lung Cell Mol Physiol 326(5):L551-L561 PMID: 38375579
- 7. Yeung ST et al.. 2025. Nerve- and airway-associated interstitial macrophages mitigate SARS-CoV-2 pathogenesis via type I interferon signaling.. Immunity 58(5):1327-1342.e5 PMID: 40286790
- 8. Schreiber G. 2017. The molecular basis for differential type I interferon signaling.. J Biol Chem 292(18):7285-7294 PMID: 28289098
